Brief: In8bio Announces Clinical Pipeline Prioritization

IN8bio

04/09/2024 21:10

Sept 4 (Reuters) - IN8BIO, Inc.  INAB.O :
    * IN8BIO ANNOUNCES CLINICAL PIPELINE PRIORITIZATION TO FOCUS
ON
INB-100 FOR ACUTE MYELOID LEUKEMIA
    * IN8BIO, INC. - A WORKFORCE REDUCTION OF 49%
    * IN8BIO, INC. - WILL SUSPEND ITS GLIOBLASTOMA (GBM)
DEVELOPMENT
PROGRAM
    * IN8BIO- SUSPENDED PATIENT ENROLLMENT IN INB-400 PHASE 2
CLINICAL
TRIAL FOR NEWLY DIAGNOSED GBM WHILE IT EXPLORES PARTNERSHIP
OPPORTUNITIES FOR PROGRAM
    * IN8BIO, INC. - EXPECTS TO INCUR ONE-TIME COSTS OF
APPROXIMATELY
$0.3 MILLION IN CONNECTION WITH WORKFORCE REDUCTION

Source text for Eikon:  ID:nGNXry1ZQ 
Further company coverage:  INAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))